Candel Therapeutics (CADL) Faces Investor Scrutiny After Surprise BLA Delay Drives Stock 26% Lower – HBSS
Globe Newswire•16/11/2026•14:05 ET
2
Key Highlights
- ➤Candel shares fell 26% after delaying aglatimagene BLA submission to mid-2027
- ➤BLA delay followed assay-refinement timelines and ongoing FDA dialogue
- ➤Hagens Berman opened an investigation into potential federal securities-law violations
- ➤Candel previously said it remained on track for a Q4 BLA submission
Expert Statements
Reed Kathrein, Hagens Berman partner leading the investigation
“We’re focused on how long Candel’s assay refinement has been underway, and whether repeated ‘on track’ assurances may have intentionally misled investors”
SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- On November 13, 2026, investors in Candel Therapeutics (NASDAQ: CADL) saw the price of their shares tumble 26% on the company’s announcement that it is delaying the submission of its biologics license application (“BLA”) for its most advanced product candidate – aglatimagene, which is intended to treat patients with prostate cancer.
In view of Candel’s previous statements about the BLA timing, the development and severe market reactions have prompted national shareholders rights firm Hagens Berman to open an investigation into whether Candel may have violated federal securities laws.
Get started
Create a free account to read the full story.
